Esperion Therapeutics was initially published as one of our 7investing Community's New Ideas in December 2024

Discuss Esperion Therapeutics in our Community Forum

Background

The following comes directly from our initial Community recommendation. 7investing's opinions may differ from the person(s) who submitted this community research.

Esperion sells a drug that is a Statin alternative where it either doesn’t have the desired effect or can not be tolerated.

Esperion holds rights in the US market which sales have been growing over 50% and licenses out the rights in Europe and Japan.

The Japan partner has just filed a NDA to the Japan ministry of health which should trigger a 20M milestone payment to Esperion.

Recent Company Updates

The following comes from our 7investing Community. 7investing's advisors opinions may differ from the person(s) who submitted this research.

March 5, 2025:

Esperion had a positive fourth quarter earnings report and shares are up 12%.

• FY24 Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million
• Q4 Total Revenue Grew 114% Y/Y to $69.1 Million; Q4 U.S. Net Product Revenue Grew 52% Y/Y to $31.6 Million
• Q4 Retail Prescription Equivalents Grew 45% Y/Y and 12% Q/Q

They focused On Three Pillars for Building a Blockbuster Company: Continued Revenue Growth, Reaching Operating Profitability, and Portfolio Expansion/Pipeline Advancement. They also announced the development of Triple Combination Products with Bempedoic Acid in the U.S.

January 21, 2025: Esperion's partners have filed with the Japanese FDA as well as Israel and Canada.

Outside of the United States, they likely are getting licensing deals with partners that will support the regions.

Investors are mostly waiting for earnings to see how well the US and Europe markets are growing while waiting for approval in other markets.